SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Whelan Jeremy S)
 

Sökning: WFRF:(Whelan Jeremy S) > High-Dose Chemother...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00006947naa a2200829 4500
001oai:lup.lub.lu.se:ffec299a-f80f-4af6-9a59-121343a8b9b9
003SwePub
008191217s2019 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/ffec299a-f80f-4af6-9a59-121343a8b9b92 URI
0247 a https://doi.org/10.1200/JCO.19.009152 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Dirksen, Utau University Hospital Essen4 aut
2451 0a High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases : Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008
264 1c 2019
300 a 11 s.
520 a PURPOSE: The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared with standard chemotherapy with WLI in Ewing sarcoma (ES) presenting with pulmonary and/or pleural metastases. METHODS: From 2000 to 2015, we enrolled patients younger than 50 years of age with newly diagnosed ES and with only pulmonary or pleural metastases. Patients received chemotherapy with six courses of vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) and one course of vincristine, dactinomycin, and ifosfamide (VAI) before either BuMel or seven courses of VAI and WLI (VAI plus WLI) by randomized assignment. The analysis was conducted as intention to treat. The estimates of the hazard ratio (HR), 95% CI, and P value were corrected for the three previous interim analyses by the inverse normal method. RESULTS: Of 543 potentially eligible patients, 287 were randomly assigned to VAI plus WLI (n = 143) or BuMel (n = 144). Selected patients requiring radiotherapy to an axial primary site were excluded from randomization to avoid excess organ toxicity from interaction between radiotherapy and busulfan. Median follow-up was 8.1 years. We did not observe any significant difference in survival outcomes between treatment groups. Event-free survival was 50.6% versus 56.6% at 3 years and 43.1% versus 52.9% at 8 years, for VAI plus WLI and BuMel patients, respectively, resulting in an HR of 0.79 (95% CI, 0.56 to 1.10; P = .16). For overall survival, the HR was 1.00 (95% CI, 0.70 to 1.44; P = .99). Four patients died as a result of BuMel-related toxicity, and none died after VAI plus WLI. Significantly more patients in the BuMel arm experienced severe acute toxicities than in the VAI plus WLI arm. CONCLUSION: In ES with pulmonary or pleural metastases, there is no clear benefit from BuMel compared with conventional VAI plus WLI.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Pediatrik0 (SwePub)302212 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Pediatrics0 (SwePub)302212 hsv//eng
7001 a Brennan, Bernadetteu Royal Manchester Children's Hospital4 aut
7001 a Le Deley, Marie Cécileu Centre Oscar Lambret,University of Paris-Saclay4 aut
7001 a Cozic, Nathalieu Institut Gustave Roussy4 aut
7001 a van den Berg, Henku Academic Medical Center of University of Amsterdam (AMC),Emma Children’s Hospital4 aut
7001 a Bhadri, Viveku Cancer Institute of New South Wales4 aut
7001 a Brichard, Bénédicteu Saint-Luc University Hospital4 aut
7001 a Claude, Lineu Centre Léon Bérard4 aut
7001 a Craft, Alanu University of Newcastle upon Tyne4 aut
7001 a Amler, Susanneu Friedrich Loeffler Institute,University of Münster4 aut
7001 a Gaspar, Natalieu Institut Gustave Roussy4 aut
7001 a Gelderblom, Hansu Leiden University Medical Centre4 aut
7001 a Goldsby, Robertu UCSF Benioff Children‘s Hospital,University of California, San Francisco4 aut
7001 a Gorlick, Richardu University of Texas4 aut
7001 a Grier, Holcombe E.u Boston Children's Hospital4 aut
7001 a Guinbretiere, Jean Marcu Hôpital René-Huguenin4 aut
7001 a Hauser, Peteru Semmelweis University4 aut
7001 a Hjorth, Larsu Lund University,Lunds universitet,Sena effekter efter barncancerbehandling,Forskargrupper vid Lunds universitet,Late effects after childhood cancer treatment,Lund University Research Groups4 aut0 (Swepub:lu)pedi-lhj
7001 a Janeway, Katherineu Boston Children's Hospital4 aut
7001 a Juergens, Heribertu University Hospital Münster4 aut
7001 a Judson, Ianu Royal Marsden NHS Foundation Trust4 aut
7001 a Krailo, Marku University of Southern California4 aut
7001 a Kruseova, Jarmilau Charles University in Prague4 aut
7001 a Kuehne, Thomasu University Children's Hospital, Basel4 aut
7001 a Ladenstein, Ruthu Medical University of Vienna4 aut
7001 a Lervat, Cyrilu Centre Oscar Lambret4 aut
7001 a Lessnick, Stephen L.u Ohio State University4 aut
7001 a Lewis, Ianu University of Leeds4 aut
7001 a Linassier, Claudeu University Hospital of Tours4 aut
7001 a Marec-Berard, Perrineu Pediatric Hematology and Oncology Institute (IHOPE)4 aut
7001 a Marina, Neyssau Five Prime Therapeutics Inc4 aut
7001 a Morland, Bruceu Birmingham Children's Hospital4 aut
7001 a Pacquement, Hélèneu Curie Institute, Paris4 aut
7001 a Paulussen, Michaelu Witten/Herdecke University4 aut
7001 a Randall, R. Loru University of California, Davis4 aut
7001 a Ranft, Andreasu Institut Gustave Roussy,University of Paris-Saclay4 aut
7001 a Le Teuff, Gwénaëlu University of Birmingham4 aut
7001 a Wheatley, Keithu University College London Hospital4 aut
7001 a Whelan, Jeremyu University of Pennsylvania,The Children's Hospital of Philadelphia4 aut
7001 a Womer, Richardu Seattle Children’s Hospital4 aut
7001 a Oberlin, Odileu Institut Gustave Roussy4 aut
7001 a Hawkins, Douglas S.u Seattle Children’s Hospital,Children's Hospital and Regional Medical Center, Seattle4 aut
7102 a University Hospital Essenb Royal Manchester Children's Hospital4 org
7102 a Euro-E.W.I.N.G. 99 Investigators
7102 a Ewing 2008 Investigators
7730 t Journal of Clinical Oncologyg 37:34, s. 3192-3202q 37:34<3192-3202x 0732-183X
8564 u http://dx.doi.org/10.1200/JCO.19.00915y FULLTEXT
8564 8u https://lup.lub.lu.se/record/ffec299a-f80f-4af6-9a59-121343a8b9b9
8564 8u https://doi.org/10.1200/JCO.19.00915

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy